Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
Author:
Funder
Canadian Institutes of Health Research
Canadian Cancer Society
Peter Gilgan Foundation
Canada Research Chairs
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-023-06991-3.pdf
Reference35 articles.
1. Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112
2. Daly MB, Pal T, Berry MP et al (2021) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(1):77–102. https://doi.org/10.6004/jnccn.2021.0001
3. Metcalfe K, Eisen A, Senter L et al (2019) International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15–21. https://doi.org/10.1038/s41416-019-0446-1
4. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7(1):46–53. https://doi.org/10.1038/nrc2048
5. Force USPST, Owens DK, Davidson KW et al (2019) Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA 322(9):857–867. https://doi.org/10.1001/jama.2019.11885
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Incidence of endometrial cancer in BRCA mutation carriers;Gynecologic Oncology;2024-10
2. Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants;International Journal of Molecular Sciences;2024-05-28
3. Exploring the connection between BRCA2 and thyroid cancer;Oncology and Translational Medicine;2024-05-24
4. Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions;Annals of Surgical Oncology;2024-01-23
5. Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers;Cancers;2023-12-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3